Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Fudan University
634 trials monitored
See 8 trials at risk
Gastric Cancer
1,281 trials monitored
See 61 trials at risk
The goal of this exploratory study is to evaluate the efficacy and safety of zeprumetostat in combination with retlirafusp alfa, apatinib, and chemotherapy as first-line treatment in patients with HER2-negative unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma who have not received prior anticancer therapy.
Trial Details
NCT Number NCT07874425
Lead Sponsor Fudan University
Conditions
(from sponsor)		 Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Related terms Stomach Neoplasms
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov